Virion Therapeutics Patents – Insights & Stats (Updated 2023)

Virion Therapeutics has a total of 20 patents globally, out of which 2 have been granted. Of these 20 patents, more than 95% patents are active. The United States of America is where Virion Therapeutics has filed the maximum number of patents, followed by South Africa and Vietnam. Parallelly, Vietnam seems to be the main focused R&D centre while the United States of America is the origin country of Virion Therapeutics.

Virion Therapeutics was founded in 2018. Virion Therapeutics is a biotechnology company which is involved in development and marketing of vaccines for cancers and chronic viral infections.

Do read about some of the most popular patents of Virion Therapeutics which have been covered by us in this article and also you can find Virion Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Virion Therapeutics patent portfolio.

How many patents does Virion Therapeutics have?

Virion Therapeutics has a total of 20 patents globally. These patents belong to 3 unique patent families. Out of 20 patents, 19 patents are active.

How Many Patents did Virion Therapeutics File Every Year?

Virion Therapeutics Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantVirion Therapeutics Applications FiledVirion Therapeutics Patents Granted
202321
202251
202113

How many Virion Therapeutics patents are Active/Inactive?

Worldwide Patents

Virion Therapeutics Patent Portfolio

How Many Patents did Virion Therapeutics File in Different Countries?

Virion Therapeutics Worldwide Patent Filing

Countries in which Virion Therapeutics Filed Patents

CountryPatent
United States Of America3
South Africa2
Viet Nam2
New Zealand1
Israel1
Canada1
Europe1
Mexico1
Hong Kong (S.A.R.)1
Singapore1
Brazil1
China1
India1
Australia1
Indonesia1

Where are Research Centers of Virion Therapeutics Patents Located?

R&D Centers of Virion Therapeutics

What Percentage of Virion Therapeutics US Patent Applications Were Granted?

Virion Therapeutics (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 100%.

Below are the key stats of Virion Therapeutics patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Virion Therapeutics?

Law FirmTotal ApplicationsSuccess Rate
Bakerhostetler2100%

List of Virion Therapeutics patents

Virion Therapeutics PatentsTitle
US11850282B2Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
US11291716B2Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
US20230063089A1Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
EP4087605A1Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
CN115335076AAdenoviral Vectors Encoding Hepatitis B Virus Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Use Thereof
ZA202310905AAdenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
VN95665AAdenovirut Vectors Encoding Hepatitis B Antibodies Fused With Glycoprotein D Of Virut Herpes And Methods Of Use There
VN94385AAdenovirut Vectors Encoding Hepatitis B Antibodies Fused With Glycoprotein D Of Virut Herpes
ZA202207167AAdenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
HK40082959AAdenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
IN202217040049AAdenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoproteind And Methods Of Using The Same
ID202206559AVector Adenovirus Encounting Hepatitis B Virus Antigen Followed To Glycoprotein D Herpes Virus And Methods Using The Same Vector
MX2022008572AAdenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same.
BR112022013620A2Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Use Thereof
SG11202251040KAAdenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
IL294387AAdenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
AU2021205936A1Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
NZ789990AAdenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
CA3166989A1Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same
WO2021142212A1Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same

What are Virion Therapeutics key innovation segments?

What Technologies are Covered by Virion Therapeutics?

The chart below distributes patents filed by Virion Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Virion Therapeutics thinks it’s important to protect particular technology inventions.

R&D Focus: How has Virion Therapeutics search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Virion Therapeutics?

Related Articles

Computime Patents – Insights & Stats (Updated 2024)

Computime has a total of 224 patents globally, out of which 115 have been granted. Of these 224 patents, more than 63% patents are active. The United States of America is where Computime has filed the maximum number of patents, followed by Europe (EPO) and Germany. Parallelly, United States of

Read More »

Leave a Comment

Fill the form to get the details:

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.